Efficacy of immediate lymphatic reconstruction after breast cancer surgery: A systematic review and time-course dynamics meta-analysis
In brief
Immediate lymphatic reconstruction cuts breast cancer lymphedema risk by about two-thirds
A meta-analysis of 17 studies found that adding immediate lymphatic reconstruction to axillary node dissection lowered the incidence of postoperative lymphedema to roughly one-third of that seen with surgery alone, with the strongest effect at 12 months after operation. The benefit appears durable for at least two years, but data beyond that are sparse, so long-term protection remains uncertain.
- Journal
- Journal of reconstructive microsurgery (Q1)
- Published
- 24 August 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Hong-Jie Chang, Kuan-Yu Chen, Wen-Kuan Chiu, Khanh Dinh Hoang, Tun-Wen Pai, Chin-Yu Sun, et al.
- PMID
- 42636877
- DOI
- 10.1055/a-2943-3724
Why clinicians should know about it
- Picked for Breast and Endocrine Surgery (paper of the day, 28 August 2026): ILR reduces lymphedema risk after axillary dissection
Abstract
BACKGROUND: Immediate lymphatic reconstruction (ILR) is a prophylactic approach for breast cancer-related lymphedema (BCRL) following axillary lymph node dissection (ALND). This study assessed the preventive effect of ILR by evaluating data from prior studies, with a focus on time-course dynamics. METHODS: A systematic review and meta-analysis was performed of 17 studies comparing ALND plus ILR with ALND alone. The primary outcome was BCRL incidence. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were stratified by follow-up duration (1-48 months). RESULTS: ILR significantly reduced BCRL incidence (RR: 0.37; 95% CI: 0.28-0.49). Time-stratified analysis indicated that the prophylactic effect was robust within the first 2 years postoperatively, peaking at 12 months (RR: 0.13; 95% CI: 0.04-0.46). Limited data beyond two years necessitates further studies to clarify long-term results. CONCLUSION: ILR reduces BCRL risk, remaining a valuable preventive strategy for breast cancer patients. This benefit remains unclear in the long term, highlighting the need for further high-quality trials with extended surveillance.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.